Trevor Lowenthal | TalkMarkets | Page 1

Trevor Lowenthal

Writer, Partner at Lowenthal Capital Partners
With emphasis on biotechnology, Trevor focuses his portfolio on undervalued micro and small-cap companies. As a contributor to TalkMarkets, he hopes to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical ...more
Following: 36 Followers: 3000

All Contributions

Latest Posts
1 to 16 of 23 Posts
1 2 >>>
Talking With NuLife's CEO About Transplants And Technology
Tuesday, August 29, 2017 10:38 AM EDT
NuLife is a very early stage, precommercialization company exploring alternatives to transplants, initially for kidney patients.
In this article: NULF
Read
Interview With First Choice Healthcare Solutions
Friday, February 17, 2017 2:52 PM EDT
I had the opportunity to interview Chris Romandetti. the CEO of First Choice Healthcare Solutions. FCHS is a network of non-physician owned medical centers. It is listed on the OTC market and trades at $1.53/share; the stock is worth a closer look.
In this article: FCHS Also: BA, COL, GE, HRS, RTN
Read
BioSig: An Emerging Medical Device Developer Making Strides In Catheter-Based Electrophysiology
Friday, March 13, 2015 1:13 PM EDT
In this exclusive interview, CEO Gregory Cash provides an overview of BioSig's business developments and future prospects.
In this article: BSGM
Read
Pfizer: A Hot Stock With New Blockbuster Breast Cancer Drug
Thursday, February 26, 2015 3:22 PM EDT
Palbociclib received accelerated FDA approval earlier this quarter. With annual sales estimates in the billions, I believe Pfizer could be a hot stock to own in 2015.
In this article: PFE
Read
Arch Therapeutics Is A Life Sciences Company To Put On Your Radar: CEO Terrance Norch
Thursday, February 26, 2015 2:42 PM EDT
In this exclusive interview, Dr. Terrance Norch highlights Arch Therapeutics' compelling value proposition.
In this article: ARTH
Read
Is China Biologic Products Poised To Tumble?
Monday, February 23, 2015 1:08 PM EDT
The company's valuation has increased exponentially in a very short period of time. With a major earnings event approaching, is it time to take profits or ride the post-earnings volatility?
In this article: CBPO
Read
Sanofi Increases Production Capacity Through Strategic Collaboration
Wednesday, January 21, 2015 12:24 PM EDT
With over 70 percent of its projects in biologics, Sanofi has been desperate for additional production capacity. The newly established strategic collaboration with a major developer should fill this need.
In this article: SNY
Read
Baxter Wins FDA Approval For PHOXILLUM
Tuesday, January 20, 2015 3:04 PM EDT
With the approval for PHOXILLUM, Baxter should improve its growth prospects amid the Baxalta spin-off.
In this article: BAX
Read
Sanofi Announces EMA Acceptance Of MAA Submission For Praluent
Monday, January 12, 2015 4:52 PM EDT
Sanofi faces a steep patent cliff, but I believe Praluent will help offset the subsequent drop in revenues.
In this article: SNY, REGN
Read
Ligand Partner Receives Orphan Drug Designation
Friday, January 9, 2015 11:32 AM EDT
With the Orphan Drug designation for Sparsentan, Ligand should improve its long-term growth prospects.
In this article: LGND
Read
Emerging Technologies: A New Antibiotic That Doesn't Cause Resistance?
Friday, January 9, 2015 2:47 AM EDT
NovoBiotic Pharmaceuticals is reportedly developing a promising antibiotic candidate that kills dangerous evolving superbugs without resistance.
In this article: APHB, OGEN
Read
Quicklegal: An Emerging Tech With A Compelling Value Proposition
Tuesday, January 6, 2015 1:18 PM EDT
Quicklegal could take the legal sector by storm.
Read
Synthetic Biologics: A Compelling Biotech With A Low Valuation
Friday, December 26, 2014 2:28 PM EDT
Synthetic Biologics has various opportunities in several lucrative clinical indications. The surprising thing is that the biotech has an incredibly low valuation compared to its competitors.
In this article: SYN
Read
Baxter On A Roll -- Wins Approval For OBIZUR
Friday, October 24, 2014 5:31 PM EDT
Baxter continues to enhance the growth prospects. Back-to-back approvals of three important treatment supports the bullish thesis.
In this article: BAX
Read
OXiGENE: First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin
Wednesday, October 8, 2014 12:04 PM EDT
OXiGENE announces that the first patient has been enrolled in the Phase 1b/2 study of fosbretabulin in combination with Votrient(TM) (pazopanib) in patients with recurrent ovarian cancer.
In this article: OXGN
Read
A Recap Of My MannKind Experience
Friday, October 3, 2014 3:31 AM EDT
Various commentators questioned my integrity and motives for my continued coverage of MannKind. This article hopes to set the record straight.
In this article: MNKD
Read
1 to 16 of 23 Posts
1 2 >>>